The isotretinoin drugs market was valued at USD 1,349.3 Mn by 2019. The rising prevalence of skin complications worldwide primarily drives the market growth. Furthermore, effective implementation of the treatment guidelines pertaining to dermatological diseases further accelerates the isotretinoin drugs market growth.

Isotretinoin is popularly known as 13-cis-retinoic acid which received approval for medicinal purposes in 1982. Dermatologists usually rely on prescribing isotretinoin in patients resistant to other medications widely employed to treat skin diseases. Pharmacologists are working diligently to develop its clinical application in the treatment of genital warts and recalcitrant condylomata acuminate of the cervix region. The drug needs to be taken under medical supervision owing to its teratogenicity effects and the possibility of causing 20% to 35% of congenital defects in infants exposed to the drug toxicity.

The major segments related to the isotretinoin drugs market are: 

By Clinical Application (2017–2027; US$ Mn)

Dermatology

Cancer

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global isotretinoin drugs market
• The overall segmentation of the isotretinoin drugs market, by clinical application, distribution channel, and geography is minutely studied. Dermatology and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
• Rising prevalence of dermatology complications worldwide
• Significant increase in the number of clinical trial investigation for determining the therapeutic efficacy and safety of isotretinoin in the treatment of cutaneous t-cell lymphomas

Report gist?

• The study of the global isotretinoin drugs market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of isotretinoin drugs due to the  rising prevalence of dermatology complications worldwide
• The report will benefit pharmacologist engaged in conducting a clinical trial investigation of isotretinoin for the treatment of cutaneous t cell lymphomas
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to isotretinoin drugs market
• Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Dermatology complications are leading the clinical application segment for the isotretinoin drug market. The rising prevalence of acne in the Caucasian population throughout the globe primarily drives the market growth. According to the latest research citings provided by the European Society for Medical Oncology (ESMO), the depletion of ozone layers has accelerated the incidence rate of skin complications in the individuals residing in the sub-tropical climate. According to the latest statistics provided by the National Institute of Health (NIH), it is estimated that 90% of the adolescent global population experiences acne at some point of their lifetime. Cancer will be registering comfortable market growth in the near future owing to the significant rise in the occurrence of squamous cell carcinoma throughout the globe. The constant rise in the clinical trial investigation of isotretinoin for its therapeutic efficacy and safety in the treatment of cutaneous t cell lymphoma will further accentuate the market growth.

Hospital pharmacy is presently spearheading the distribution channel segment for the isotretinoin drug market. The drug is associated with teratogenicity effects, hence accurate drug compounding under the supervision of hospital pharmacists is mandatory in order to avoid the occurrence of a drug overdose. Retail pharmacy is expected to highlight impressive market growth in the developing region primarily due to the provision of cheap generic medicines due to government subsidy on essential medicines and constant rise in the generic drug manufacturing across the globe.

North America is currently reigning the geography segment for the isotretinoin drug market. The rising prevalence of dermatological complications primarily determines the market growth in the region. As per the latest statistics provided by the American Academy of Dermatology (AAD), approximately 40 million people in the United States suffer from acne. Additionally, favorable reimbursement scenario and domicile of key players such as Teva Pharmaceutical Industries Limited, Mylan Pharmaceutical Industries Ltd, F.Hoffmann-La Roche Ltd., etc. further consolidates the market growth in the region. Europe is the second-largest regional segment on account of the rising prevalence of cutaneous t-cell lymphoma in the Caucasian population residing in the region. Asia Pacific is anticipated to be the fastest-growing regional segment during the forecast period. Flourishing generic drugs market and effective implementation regarding the treatment guidelines pertaining to the treatment of skin complications determine the isotretinoin drugs market growth in the Asia Pacific region.